More News! 16 Apr 2018Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases The British-Belgian biotech Apitope has obtained positive Phase I results for its first-in-class treatment for Graves' disease, one of the… April 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2017Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on… November 1, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 May 2017What Happens when the Immune System Attacks Life-Saving Drugs? Immunogenicity has been largely disregarded despite its huge impact on the performance of biological drugs. What is it and how… May 24, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2017A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed… February 21, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2015Apitope relocates to Wales after €12M series B financing round Now, as we've recently discussed here at Labiotech, there doesn't appear to be many Welsh biotechs...however, this is all about… September 30, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email